BiotechTube

Cinitapride + domperidone

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dyspepsia

Conditions

Dyspepsia

Trial Timeline

Oct 1, 2010 → Oct 1, 2011

NCT ID
NCT01355276

About Cinitapride + domperidone

Cinitapride + domperidone is a phase 3 stage product being developed by Eisai for Dyspepsia. The current trial status is completed. This product is registered under clinical trial identifier NCT01355276. Target conditions include Dyspepsia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01355276Phase 3Completed

Competing Products

20 competing products in Dyspepsia

See all competitors
ProductCompanyStageHype Score
YH12852 0.1 mg + YH12852 0.25 mg + YH12852 0.5 mg + PlaceboYuhanPhase 2
52
YM443 + Placebo + MoxifloxacinAstellas PharmaPhase 1
33
YM443Astellas PharmaPhase 3
77
Rabeprazole + Rabeprazole + Rabeprazole + PlaceboEisaiPhase 2
52
Z-338Zeria PharmaceuticalPhase 3
76
Imonogas + EspumisanJohnson & JohnsonPhase 3
77
esomeprazoleAstraZenecaApproved
85
Esomeprazole MagnesiumAstraZenecaApproved
85
TegaserodNovartisPhase 3
77
TegaserodNovartisPhase 3
77
TegaserodNovartisPhase 3
77
Tegaserod and PlaceboNovartisApproved
85
TegaserodNovartisPhase 3
77
TegaserodNovartisPhase 3
77
Gabapentin + PlaceboPfizerPhase 3
76
Z-338Zeria PharmaceuticalPhase 2
51
Z-338Zeria PharmaceuticalPhase 2
51
Z-338Zeria PharmaceuticalPhase 2
51
Z-338 + PlaceboZeria PharmaceuticalPhase 3
76
Acotiamide hydrochloride hydrate + PlaceboZeria PharmaceuticalPhase 3
76

Other Products from Eisai

MecobalaminApproved
85
MonteplaseApproved
85
E2020 + PlaceboApproved
85
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved
85
DonepezilApproved
85